论文部分内容阅读
目的研究荷瘤小鼠骨髓来源的树突状细胞（ＤＣ）是否具有诱导机体产生抗肿瘤免疫反应的能力， 与正常小鼠骨髓来源的ＤＣ有无差异。方法于体外用ｍＧＭ－ＣＳＦ和ｍＩＬ－４分别从正常小鼠和荷Ｃ２６肿瘤的小鼠骨 髓细胞诱导产生ＤＣ，观察它们刺激同种Ｔ细胞、同基因Ｔ细胞增殖的能力，以及由二者免疫所诱导产生的ＣＴＬ的 杀伤活性。结果荷瘤小鼠骨髓来源的ＤＣ与正常小鼠骨髓来源的ＤＣ在刺激同种Ｔ细胞增殖、刺激同基因Ｔ细胞 增殖的能力和诱导产生ＣＴＬ的杀伤活性差异无显著意义。结论荷瘤小鼠骨髓来源的ＤＣ与正常鼠骨髓来源的 ＤＣ具有相似的诱导产生抗肿瘤免疫反应的能力，提示可以从荷瘤机体的ＤＣ前体诱导产生有抗瘤能力的ＤＣ，用于 抗肿瘤免疫治疗。
Objective To investigate whether bone marrow-derived dendritic cells (DCs) in tumor-bearing mice have the ability to induce the body to produce anti-tumor immune responses and have no difference with bone marrow-derived DCs in normal mice. Methods DCs were induced in vitro from mGM-CSF and mIL-4 mouse bone marrow cells from normal and C26 tumor-bearing mice, respectively, and their ability to stimulate allo-T cells, syngeneic T cell proliferation, and immunization with both Induced CTL killing activity. Results There was no significant difference between the DCs of bone marrow derived from tumor-bearing mice and those from normal mouse bone marrow in stimulating allogeneic T cell proliferation, stimulating the proliferation of syngeneic T cells and inducing CTL. Conclusion Bone marrow-derived DCs in tumor-bearing mice have a similar ability to induce anti-tumor immune responses from DCs derived from normal mouse bone marrow, suggesting that DCs with tumor-bearing ability can be induced from DC precursors of tumor-bearing mice for anti- Tumor immunotherapy.